Glycorex Transplantation Ab Class B · NGM:GTAB.B
Glycorex Transplantation Ab Class B — BioStock Life Science Spring Summit 2021
16 slides from Glycorex Transplantation Ab Class B's conference presentation, May 26, 2021
Slide 1: BioStock Life Science Spring Summit
BioStock Life Science Spring Summit May 26, 2021 Pontus Nobréus CEO Glycorex Transplantation AB
Slide 2: Global burden of kidney failure – a major and rising problem
Global burden of kidney failure – a major and rising problem Nature reviews Nephrology, volume 16, Oct 2020 The current and future landscape of dialysis
Slide 3: Kidney failure – large impact on the individual and the society
Kidney failure – large impact on the individual and the society Challenging situation in the US: • More than 37 millions with chronic kidney disease • >726,000 Americans need dialysis or kidney transplants to survive • >500,000 receive dialysis three times a week ”Many developed countries spend 2–3%
Slide 4: Challenges with kidney transplantations
Challenges with kidney transplantations Gap between supply and demand ABO incompatible blood groups Kidney Paired Donation (KPD) O A B AB U.S. Government Information on Organ Donation and Transplantation (www.organdonor.gov) National Kidney Foundation
Slide 5: Glycosorb® ABO enables transplants regardless of blood group
Glycosorb® ABO enables transplants regardless of blood group
Slide 6: Glycosorb® ABO works with standard plasma separation systems
Glycosorb® ABO works with standard plasma separation systems
Slide 7: In clinical use since 2001 > 60 publications
In clinical use since 2001 > 60 publications > 5,000 transplantations 200 centers in ~ 30 countries
Slide 8: Global transplantations trends
Global transplantations trends 160 000 120 000 140 000 100 000 120 000 80 000 100 000 80 000 60 000 60 000 40 000 40 000 20 000 20 000 0 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Kidney Liver Heart Lung Pancreas Small bowel Kidney DD Kidney
Slide 9: Top 25 countries Living Donor Kidney transplantations 2019
Top 25 countries Living Donor Kidney transplantations 2019 10 000 9 000 8 000 7 000 6 000 5 000 4 000 3 000 2 000 1 000 0 l y an ia o ria m a A ey a n ic s ina ly ea da n ce en bia il bia ain ae nd an ali pa in ic US az tio d bl do Ita an d ge or rk na ed Is r ex Ch In nt lom ra Sp rla Br str pu rm
Slide 10: Glycosorb® ABO - large market potential Living Donor Kidney transplantations
Glycosorb® ABO - large market potential Living Donor Kidney transplantations Number of annual global Europe Kidney transplantations > 100 million SEK ~ 98 000 Annual Living donor Kidney India, Mexico & Turkey transplantations >125 million SEK ~ 36 000 Estimated number of annual blood group incompati
Slide 11: Increasing number of blood group incompatible transplantations with Glycosorb® ABO
Increasing number of blood group incompatible transplantations with Glycosorb® ABO 25,0% Glycosorb® ABO Germany 20,0% 15,0% 10,0% 5,0% Plasma exchange USA 0,0% 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Tyskland USA
Slide 12: Blood plasma – an important tool for health care providers
Blood plasma – an important tool for health care providers Blood transfusion given to patients in many circumstances Critical factors in massive transfusion protocols: such as: • Time between trauma and transfusion • Serious injuries • Transport of plasma from blood bank to the clinical unit • Surge
Slide 13: Glycosorb® ABO – designed to enable access to universal blood plasma
Glycosorb® ABO – designed to enable access to universal blood plasma Glycosorb® ABO makes it possible to: • Improve stock keeping and logistics for the blood bank • Reduce risk for transfusion mistakes and delays Estimated market for universal blood plasma in EU: • Provide access to adequate blood p
Slide 14: R&D Pipeline – focus on autoimmune diseases
R&D Pipeline – focus on autoimmune diseases Rheumatoid Arthritis (RA) Other projects • 5 million people in EU • Myasthenia Gravis (MG) • No cure – immunosuppressive and anti- • Impact on muscle inflammatory drugs – up to 10% do not function respond • Typically treated with • Potential market in EU e
Slide 15: Main priorities 2021
Main priorities 2021 • Living Donor Kidney Transplantation market • Europe • Emerging markets – India, Mexico, Turkey • FDA registration work in the US • Commercialization of UBP-product • Pre-launch selected customers • Ambition to include UBP-product in scientific publications • Optimize and inten
Slide 16: Thank you!
Transplantation eeG lyc ore ~ = <_< ae
Glycorex Transplantation — BioStock Life Science Spring Summit 2021 on 6ix